Table 1.
SPMM estimates
| Subject ID | K | Days post infection with 95% CI | P # | SSE |
|---|---|---|---|---|
| Heterosexual | ||||
| SC33 | 2 | 22.4 [14.8–30.1] | 0.040 | 0.0049 (1053.2) |
| TT27P | 3 | 10.8 [6.4–15.2] | 0.33 | 0.0020 (1538.3) |
| CAP8a | 2 (1) | 49.1 [35.4–62.9] | 0.18 | 0.0032 (612.6) |
| CAP224 | 2 | 20.2 [11.7–28.8] | 0.57 | 0.0091 (510.7) |
| 703010228 | 2 | 21.3 [13.9–28.7] | 0.89 | 0.0010 (1040.4) |
| SC31a | 2 (1) | 24.2 [17.4–31.1] | 0.095 | 0.019 (2104.2) |
| CAP222a | 4 (3) | 14.0 [7.2–20.8] | 0.071 | 0.0063 (564.9) |
| 0478a | 2 (3) | 54.2 [40.3–68.2] | 0.021 | 0.011 (721.7) |
| 703010010 | 3 | 11.9 [5.8–18.0] | <0.0001 | 0.039 (631.0) |
| CAP136 | 2 | 36.7 [23.2–50.2] | 0.33 | 0.0085 (327.1) |
| CAP260 | 2 | 28.3 [14.9–41.7] | 0.45 | 0.018 (186.1) |
| Z30 | 2 | 64.0 [50.2–77.9] | 0.15 | 0.0062 (1040.1) |
| CAP37 | 3 | 46.1 [33.3–58.9] | 0.55 | 0.024 (839.6) |
| 0114 | 3 | 32.3 [22.5–42.0] | 0.82 | 0.0012 (861.7) |
| 703010200a | 4 (3) | 42.0 [28.6–54.6] | 0.89 | 0.013 (497.5) |
| 1335 | 3 | 28.4 [18.4–38.4] | 0.32 | 0.012 (617.8) |
| 706010151a | 3 (2) | 49.2 [31.8–66.6] | 0.044 | 0.023 (257.5) |
| CAP69a | 7 (5) | 4.8 [0.095–9.41] | 0.85 | 0.0074 (205.4) |
| 1196 | 3 | 49.5 [36.9–62.1] | 0.40 | 0.017 (884.2) |
| MSM | ||||
| Z35 | 2 | 19.3 [11.1–27.5] | 0.20 | 0.050 (571.9) |
| CAAN5342a | 2 (>2) | 30.2 [22.0–38.5] | 0.49 | 0.017 (1547.5) |
| Z16a | 4 (5) | 65.7 [49.4–82.0] | 0.97 | 0.0038 (575.9) |
| BORI0637 | 5 | 17.2 [10.1–24.3] | 0.84 | 0.0055 (698.3) |
| Z18a | 4 (3) | 33.2 [24.2–42.2] | 0.039 | 0.024 (1425.1) |
| Z03a | 2 (3) | 102.3 [83.1–121.6] | 0.39 | 0.034 (859.9) |
| IDU | ||||
| HDNDRPI029a | 2 (1) | 56.0 [44.5–67.6] | <0.0001 | 0.012 (1820.7) |
| HDNDRPI032 | 3 | 53.4 [39.6–67.2] | 0.87 | 0.0098 (682.2) |
| HTM319a | 8 (3) | 50.1 [36.4–63.9] | 0.00019 | 0.0047 (662.7) |
| PSL024 | 4 | 50.5 [33.5–67.5] | <0.0001 | 0.029 (303.5) |
| HDNDRPI001a | 4 (5) | 67.3 [49.6–84.9] | 0.0047 | 0.0090 (480.4) |
| I034-3 | 8 | 123.2 [113.6–132.7] | <0.0001 | 0.014 (28068.0) |
| 700010019a | 6 (>3) | 15.0 [7.3–22. 7] | 0.62 | 0.018 (417.5) |
| HDNDRPI034a | 9 (16) | 30.0 [23.6–36.3] | 0.08 | 0.0064 (4163.5) |
| Risk g roup u nknown | ||||
| 9076-08 | 2 | 13.5 [8.1–18.9] | 0.74 | 0.0040 (1153.4) |
| 62615-03 | 3 | 9.3 [4.6–14.0] | 0.36 | 0.0042 (809.7) |
| 9026-07 | 2 | 14.0 [6.0–22.0] | 0.97 | 0.011 (275.1) |
| 12008-09 | 2 | 8.0 [3.5–12.5] | 0.61 | 0.0079 (751.7) |
| PRB957-06a | 3 (4) | 52.5 [42.0–63.0] | <0.0001 | 0.047 (2355.0) |
| 63068-05 | 2 | 13.3 [6.3–20.2] | 0.34 | 0.030 (441.8) |
| 701010016 | 2 | 49.4 [35.6–63.2] | 0.14 | 0.0095 (622.2) |
| 1051-12a | 3 (4) | 29.9 [23.5–36.4] | <0.0001 | 0.015 (4530.4) |
aSubjects who were estimated to have a different number of founder strains using phylogenetic methods (Previously-published, phylogenetic tree-based estimates for the number of founder viruses are presented in parenthesis).
#Less than 0.05 implies statistically significant deviation from the SPMM.